Ligand director Jason Aryeh proposes $90.2K share sale

The notice also lists three prior sales by Aryeh during the past three months.

Available on EDGAR 11/04/2026 - 04:42 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:42 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc (LGND) director Jason Aryeh reported a proposed sale of 282 Class B common shares, with an aggregate market value of $90,225.50. The notice lists Nasdaq as the exchange and November 4, 2026, as the approximate sale date.

The notice identifies the shares as a secondary-market purchase and remarks that they were acquired between May 14, 2019, and July 30, 2019. It also lists prior sales by Aryeh: 1,209 shares for $385,185.47 and 202 shares for $64,738.00 on October 30, 2026, and 700 shares for $221,595.09 on November 2, 2026.

Key Figures

Proposed sale: 282 shares Aggregate market value of proposed sale: $90,225.50 Class B common shares outstanding: 20,002,986 shares +3 more

6 metrics

Proposed sale 282 shares Class B common; approximate sale date November 4, 2026

Aggregate market value of proposed sale $90,225.50 Class B common

Class B common shares outstanding 20,002,986 shares Reported in the securities information

Reported sale on October 30, 2026 1,209 shares; $385,185.47 Listed among sales during the past three months

Reported sale on October 30, 2026 202 shares; $64,738.00 Listed among sales during the past three months

Reported sale on November 2, 2026 700 shares; $221,595.09 Listed among sales during the past three months

Key Terms

Rule 144, Secondary Market Purchase, Class B common

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Secondary Market Purchase financial

"Secondary Market Purchase"

Class B common financial

"Class B common"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares did Jason Aryeh propose to sell?

Jason Aryeh's notice lists a proposed sale of 282 Class B common shares with an aggregate market value of $90,225.50. It gives November 4, 2026, as the approximate sale date and Nasdaq as the exchange.

What prior LGND sales did Jason Aryeh report?

The notice lists 1,209 shares for $385,185.47 and 202 shares for $64,738.00 on October 30, 2026, plus 700 shares for $221,595.09 on November 2, 2026. These appear in the notice's section for sales during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001376960
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIGAND PHARMACEUTICALS INC
SEC File Number	001-33093
Address of Issuer	3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CALIFORNIA 92121
Phone	858-550-7500
Name of Person for Whose Account the Securities are To Be Sold	Aryeh Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class B common	Wells Fargo Clearing Sevices 1 North Jefferson Avenue St. Louis MO 63103	282	90225.50	20002986	11/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class B common	05/14/2019	Secondary Market Purchase	Secondary Market			282	05/14/2019	cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	10/30/2026	1209	385185.47
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	10/30/2026	202	64738.00
Jason Aryeh 555 Heritage Drive Suite 200 Jupiter FL 33458	Ligand Pharmaceuticals, Inc.	11/02/2026	700	221595.09

144: Remarks and Signature

Remarks	shares were acquired between 05/14/2019 to 07/30/2019.
Date of Notice	11/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Jason Aryeh
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)